EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
Questran is used for:
- Primary prevention of coronary heart disease in men between 35 and 59 years of age and with primary hypercholesterolaemia who have not responded to diet and other appropriate measures.
- Reduction of plasma cholesterol in hypercholesterolaemia, particularly in those patients who have been diagnosed as Fredrickson's Type II (high plasma cholesterol with normal or slightly elevated triglycerides).
- Relief of pruritus associated with partial biliary obstruction and primary biliary cirrhosis.
- Relief of diarrhoea associated with ileal resection, Crohn's disease, vagotomy and diabetic vagal neuropathy.
- Management of radiation-induced diarrhoea.
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Bile acid sequestrants (anion exchange resins).
Colestyramine [cholestyramine] - diarrhoea
Questran Light: low sugar powder in sachets. Questran: powder in sachets.
Questran Light: Colestyramine 4g. Questran: Colestyramine 4g.
Questran is used for:
- Primary prevention of coronary heart disease in men between 35 and 59 years of age and with primary hypercholesterolaemia who have not responded to diet and other appropriate measures.
- Reduction of plasma cholesterol in hypercholesterolaemia, particularly in those patients who have been diagnosed as Fredrickson's Type II (high plasma cholesterol with normal or slightly elevated triglycerides).
- Relief of pruritus associated with partial biliary obstruction and primary biliary cirrhosis.
- Relief of diarrhoea associated with ileal resection, Crohn's disease, vagotomy and diabetic vagal neuropathy.
- Management of radiation-induced diarrhoea.
Adults:
As a precautionary measure, where concurrent drug therapy exists then such drugs should be administered at least one hour before or 4-6 hours after Questran.
Questran should not be taken in its dry form.
Questran should be administered mixed with water or a suitable liquid, such as fruit juice, and stirred to a uniform consistency.
Questran may also be mixed with skimmed milk, thin soups, pulpy fruits with high moisture content, e.g. apple sauce, etc..
1. For primary prevention of coronary heart disease and to reduce cholesterol: After initial introduction over a three to four week period, 3 to 6 Questran sachets per day, administered either as a single daily dose or in divided doses up to four times daily, according to dosage requirements and patient acceptability. Dosage may be modified according to response and can be increased to 9 sachets per day if necessary.
Occasional slight gastro-intestinal upsets, e.g. constipation, may occur when starting Questran. These usually pass with continued usage of Questran and are minimised by starting therapy gradually.
|
Final dose required |
Week 1 |
Week 2 |
Week 3 |
Week 4 |
|
Sachets per day |
||||
|
3 |
1 |
2 |
3 |
3 |
|
4 |
1 |
2 |
3 |
4 |
|
6 |
1 |
2 |
3 |
6 |
2. To relieve pruritus: One or two sachets daily are usually sufficient.
3. To relieve diarrhoea: As for reduction of cholesterol but it may be possible to reduce this dosage. In all patients presenting with diarrhoea induced by bile acid malabsorption, if a response is not seen within 3 days, then alternative therapy should be initiated.
Children 6 - 12 years:
The initial dose is determined by the following formula:
Subsequent dosage adjustment may be necessary where clinically indicated.
Children under 6 years: The dose has not been established in infants and children under 6 years.
Elderly:
No dosage adjustment is necessary.
Under 6 years, not recommended; over 6 years, in proportion to dose for 70 kg adult.
Questran is contra-indicated in patients who have shown hypersensitivity to any of the product ingredients.
In patients with complete biliary obstruction, since Questran cannot be effective where bile is not secreted into the intestine.
Reduction of serum folate concentrations has been reported in children with familial hypercholesterolaemia. Supplementation with folic acid should be considered in these cases.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Take all drugs 1 hour before or 4 - 6 hours after Questran.
Increased bleeding tendency on long term therapy due to vitamin K deficiency. Constipation.
Bristol-Myers Squibb
(POM)
04 October 2010





